Top Markets
#1 NKN NKN +150.21%
#2 Black Phoenix Black Phoenix +99.33%
#3 Liquid Mercury Liquid Mercury +33.08%
#4 Codatta Codatta +25.76%
#5 Saakuru Saakuru +23.97%
#6 Arcblock Arcblock +17.43%
#7 Bedrock Bedrock +16.58%
#8 pippin pippin +11.91%
#9 Bless Bless +11.44%
#10 StakeStone StakeStone +10.88%
Coin of the day
NKN NKN
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Classifica tra le azioni #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Prezzo delle azioni
$207.15
Capitalizzazione di mercato
$366.28B
Variazione (1 giorno)
0.99%
Variazione (1 anno)
2.91%
Paese
US
Scambia AbbVie Inc. (ABBV)

Categoria

Healthcare
Storico del prezzo dell'azione per AbbVie Inc. (ABBV)
Prezzo di chiusura più alto: $220.67 il 2026-03-01

Prezzo di chiusura più basso: $35.68 il 2013-01-01
Storico del prezzo dell'azione di AbbVie Inc. dal 2013 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -7.43%
2025 28.51%
2024 16.39%
2023 -7.17%
2022 27.60%
2021 21.67%
2020 19.07%
2019 0.53%
2018 -9.28%
2017 57.12%
2016 7.67%
2015 -15.03%
2014 29.37%
2013 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Eli Lilly Eli Lilly
Eli Lilly
LLY.US
 $916.42 10.84%
US
AstraZeneca PLC AstraZeneca PLC
AstraZeneca PLC
AZN.US
 $187.14 157.34%
GB
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $239.93 48.36%
US
Novartis AG Novartis AG
Novartis AG
NVS.US
 $150.75 36.87%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $119.37 35.48%
US